Supriya Lifescience

Quick check

The five things to look at first. Open one for more.

• DebtAdequate safetyRated A by ICRA.
• ResultsProfit fallingIn the Jun 2026 quarter, sales rose 31% and profit fell 31% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 68% of the company, about the same as in Jun 2025.
• ValuationExpensive vs its pastThe share trades at 33.1 times its yearly earnings (P/E), pricier than 82% of the time in the last 5 years. Its usual P/E is about 28.

Supriya Lifescience against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)33.1 against a typical 34: cheaper than most peers (1st = cheapest).107th of 220
• Sales growth+31% against a typical +15.6% from a year earlier.55th of 197
• Profit growth−31.4% against a typical +18.9% from a year earlier.121st of 160
• Share price, 3 months+0.6% against a typical −0.5%.93rd of 200
• Size₹ 6,590.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).50th of 199

Exchange filings and their impact on the company.

• 19 Oct 2026General UpdatesLow impactPositivePrice −1.4% that day
  Supreme Court admitted the pending case and granted interim protection from coercive action against directors and officers.

  Supriya Lifescience said the Supreme Court has admitted its pending judicial matter and listed it for hearing. As interim relief, the Court directed that no coercive action be taken against the directors, officers and officials of the petitioner, subject to the order's conditions. The matter remains sub judice and the company said it will update on material developments.

  Full analysisFiling
• 13 Oct 2026General UpdatesLow impactPositivePrice +1.7% that day
  CRISIL assigned Supriya Lifescience a Strong ESG score of 65 with no immediate financial impact.

  Supriya Lifescience said CRISIL ESG Ratings & Analytics has assigned it an ESG rating of CRISIL ESG 65 in the Strong category. The disclosure was made under SEBI LODR Regulation 30 on October 13, 2026. The rating is a reputational positive but carries no order, revenue or borrowing impact for the next 12 months.

  Full analysisFiling
• 8 Oct 2026General UpdatesLow impactNeutralPrice −1.6% on 9 Oct
  Supriya Lifescience has moved the High Court matter to the Supreme Court, with no financial impact disclosed yet.

  Supriya Lifescience said on October 8, 2026 that it has filed a petition before the Supreme Court of India, following up on its September 23, 2026 disclosure about a High Court order. The company said the matter is sub judice and did not comment on merits or possible outcome. It will update exchanges on any material developments as they arise.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Satish Waman Wagh

Executive Chairman of the Board

Krishna Raghunathan

Chief Financial Officer

Prachi Sathe

Company Secretary and Compliance Officer

Saloni Satish Wagh

Managing Director, Whole-Time Director

Shivani Satish Wagh

Joint Managing Director, Whole-Time Director

Balasaheb Gulabrao Sawant

Whole-Time Director

Smita Satish Wagh

Whole-Time Director